Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

Imatinib mesylate is a potent, molecularly targeted therapy against the oncogenic tyrosine kinase BCR-ABL. Although imatinib mesylate has considerable efficacy against chronic myeloid leukemia (CML), advanced-stage CML patients frequently become refractory to this agent. The bone marrow is the predo...

Full description

Saved in:

Bibliographic Details
Main Authors:	Bewry, Nadine N., Nair, Rajesh R., Emmons, Michael F., Boulware, David, Pinilla-Ibarz, Javier, Hazlehurst, Lori A.
Format:	Artigo
Language:	Inglês
Published:	2008
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2676735/ https://ncbi.nlm.nih.gov/pubmed/18852120 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-08-0314
Tags:	Add Tag No Tags, Be the first to tag this record!

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

Similar Items